Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

SciSparc Ltd. - Ordinary Shares (NQ:SPRC)

1.400 -0.070 (-4.76%)
Streaming Delayed Price Updated: 2:08 PM EST, Dec 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about SciSparc Ltd. - Ordinary Shares

< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
News headline image
Cannabis Stock Movers For August 3, 2023 ↗
 
Via Benzinga
News headline image
Clearmind Medicine Files Patent Application with USPTO for the Treatment of Dyskinesia; Further Strengthens its Already Robust IP Portfolio
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
Marijuana Stock Movers For August 2, 2023 ↗
 
Via Benzinga
News headline image
SciSparc and Clearmind Collaboration Continues to Increase its Patent Portfolio in the Field of Movement Abnormalities in the U.S.
From SciSparc Ltd
Via GlobeNewswire
News headline image
EXCLUSIVE: Clearmind Medicine Files US Patent Application For Dyskinesia Treatment, Strengthening Its IP Portfolio ↗
Clearmind Medicine Inc (NASDAQ: CMND) has announced the filing of a provisional patent application for the treatment of Dyskinesia with the United States Patent and Trademark Office (USPTO) as part of... 
Via Benzinga
News headline image
Marijuana Stock Movers For July 31, 2023 ↗
 
Via Benzinga
News headline image
Cannabis Stock Gainers And Losers From July 28, 2023 ↗
 
Via Benzinga
News headline image
Cannabis Stock Gainers And Losers From July 25, 2023 ↗
 
Via Benzinga
News headline image
SciSparc to Commence Its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc To Conduct Clinical Trial For Dronabinol-Based Drug To Treat Tourette Syndrome In Germany ↗
SciSparc Ltd. (NASDAQ: SPRC) has been granted an approval from the Federal Institute for Drugs and Medical Devices in Germany (“BfArM”) for its phase IIb clinical trial to use SCI-110 for treating... 
Via Benzinga
News headline image
SciSparc Receives Approval to Conduct Phase IIb Clinical Trial for SCI-110 to Treat Tourette Syndrome in Germany
From SciSparc Ltd
Via GlobeNewswire
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗
We're starting off Wednesday with a breakdown of the biggest pre-market stock movers traders will want to keep an eye on! 
Via InvestorPlace
News headline image
SciSparc Announces IRB Approval to Conduct its Phase IIb Trial in Tourette Syndrome
From SciSparc Ltd
Via GlobeNewswire
News headline image
EXCLUSIVE: SciSparc's Tourette Syndrome Candidate Receives IRB Approval To Start Phase 2b Study In US ↗
SciSparc Ltd (NASDAQ: SPRC) has received Institutional Review Board (IRB) approval for its Phase 2b clinical trial for SCI-110 in subjects suffering from Tourette Syndrome. Tourette Syndrome is a... 
Via Benzinga
News headline image
Clearmind Medicine and SciSparc to Conduct Study Evaluating Combination Treatment for Obesity and Metabolic Syndrome
From Clearmind Medicine Inc.
Via GlobeNewswire
News headline image
SciSparc and Clearmind Medicine to Conduct a Study Evaluating Their Combination Treatment for Obesity and Metabolic Syndrome
From SciSparc Ltd
Via GlobeNewswire
News headline image
Exclusive: Clearmind And SciSparc To Conduct Study Evaluating Psychedelics And CannAmide Based Drug For Treatment Of Obesity And Metabolic Syndrome ↗
Clearmind Medicine Inc. (NASDAQ: CMND) (CSE:CMND) (FSE:CWY) announced that as part of the company's ongoing collaboration with SciSparc Ltd. 
Via Benzinga
News headline image
The 7 Most Promising Penny Stocks to Buy in June ↗
These top penny stocks for June look to have legitimate catalysts that can certainly send share prices higher. 
Via InvestorPlace
News headline image
SciSparc Nutraceuticals Granted An Exclusive License For The Sales Of CannAmide On The Amazon Marketplace In Canada ↗
Jeffs' Brands Ltd (NASDAQ: JFBR), a data-driven e-commerce company operating on the Amazon Marketplace, announced that SciSparc Nutraceuticals Inc., in which the company owns a 49% equity interest, has... 
Via Benzinga
News headline image
Jeffs' Brands: SciSparc Nutraceuticals was Granted an Exclusive License for the Sales of CannAmide™ on the Amazon Marketplace in Canada
From Jeffs' Brands Ltd
Via GlobeNewswire
News headline image
SciSparc Grants an Exclusive License for the Sales of CannAmide™ on the Amazon Marketplace in Canada to SciSparc Nutraceuticals
From SciSparc Ltd
Via GlobeNewswire
News headline image
Why A National Cannabis Organization Sacked Half Its Staff, CEO Turnovers And More Exec Changes ↗
NCIA Sacks Half Of Its Team To Increase Financial Strength 
Via Benzinga
News headline image
New Drug Based On FDA-Approved Synthetic THC And CannAmide Shows Promise In Treating Agitation In Alzhemier's ↗
SciSparc Ltd. 
Via Benzinga
News headline image
SciSparc Announces Successful Final Phase IIa Results, Meeting End Points of its Phase IIa Alzheimer Disease Patients with Agitation Trial
Topline results using the Company's SCI-110 met the trial’s primary and secondary end points, demonstrating high safety profile and reduced agitation 
From SciSparc Ltd
Via GlobeNewswire
News headline image
Why Guidewire Software Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Gainers MultiMetaVerse Holdings Limited (NASDAQ: MMV) gained 236% to $3.1592 after the company announced it signed a non-binding term sheet to acquire an equity stake in Taomee group. 
Via Benzinga
News headline image
SciSparc Makes Another Step Towards Unlocking Potential Value Appoints New Strategy and Business Development VP
From SciSparc Ltd
Via GlobeNewswire
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗
Pre-market stock movers are a hot topic on Monday as we dive into the biggest winners and losers traders need to know about this morning! 
Via InvestorPlace
News headline image
SciSparc's Drug Discovery Joint Venture MitoCareX Bio Successfully Developed its Core Algorithm to allow suitable Modelling of Human Mitochondrial Carriers for Accelerating its Cancer Drug Discovery Program
From SciSparc Ltd
Via GlobeNewswire
News headline image
SciSparc Completed Treatment of Last Patient Enrolled for its Phase IIa Clinical Trial for Alzheimer's Disease and Agitation
From SciSparc Ltd
Via GlobeNewswire
News headline image
Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More ↗
LSD Trial Study Shows Potential For Major Depression Psychedelics biopharma company Mind Medicine Inc. (NASDAQ: MNMD) recently shared positive topline data from an advanced clinical trial of LSD as a... 
Via Benzinga
< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.